New Material Transfer Agreements Give Resolution Access to Leading Lipid Nanoparticle Technologies to Advance In Vivo RMT Development
EDINBURGH, United Kingdom and London, June 17, 2026 – Resolution Therapeutics Limited, a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy in inflammatory and fibrotic diseases, today announced an expansion of its development pipeline through a new in vivo Regenerative Macrophage Therapy program.
The company has entered into Material Transfer Agreements with independent lipid nanoparticle technology providers. These agreements will allow Resolution to assess leading LNP formulations for their ability to deliver the company’s proprietary payloads and support the engineering of the myeloid compartment in vivo.
Resolution expects preliminary results from the assessments later this year. The company said the program is designed to complement its existing autologous engineered Regenerative Macrophage Therapy platform, including RTX001, its lead clinical-stage asset currently being evaluated in a Phase 1/2 study.
In Vivo Program Designed to Broaden the Reach of Regenerative Macrophage Therapy
Resolution Therapeutics is building the in vivo program to extend the potential reach of Regenerative Macrophage Therapy to a wider patient population. The approach is intended to support the delivery of proprietary mRNA payloads through scalable lipid nanoparticle technology, with the goal of enabling macrophage engineering inside the body.
The company said the program reflects a deliberate fast-fail development strategy. By testing multiple carefully selected LNP formulations in parallel, Resolution aims to identify the most suitable delivery vehicle more efficiently while reducing development uncertainty.
If a strong LNP and payload pairing is confirmed, the results could directly support lead nomination studies. Resolution said the ideal pairing would show efficient encapsulation, targeted delivery, and expression of the mRNA payload without pushing macrophages toward an inflammatory phenotype.
LNP Formulations to Be Tested Through Systematic Assessment
Under the Material Transfer Agreements, Resolution will conduct structured assessments of differentiated LNP formulations from independent technology providers. The goal is to evaluate how effectively these formulations can support delivery into the myeloid compartment.
Lipid nanoparticles have become an important delivery modality for non-integrating in vivo therapies. However, Resolution noted that successful delivery depends on matching the right delivery system with the right payload and target cell type.
For Resolution, the key question is whether selected LNPs can deliver proprietary payloads to macrophage-related cells in a way that supports the company’s regenerative therapeutic strategy. The company believes this data-driven approach can help define the technical foundation for an in vivo RMT platform.
Program Complements RTX001 Autologous Therapy
The new in vivo program will run alongside Resolution’s autologous engineered Regenerative Macrophage Therapy program. The company’s lead asset, RTX001, is currently being evaluated in the Phase 1/2 EMERALD clinical study.
EMERALD is being conducted in patients with end-stage liver disease who have a history of decompensated liver cirrhosis. This is a patient population with limited treatment options, where liver transplant is often the only available alternative.
By advancing both autologous and in vivo platforms, Resolution aims to build a broader therapeutic strategy. The autologous program allows the company to develop engineered macrophage therapy through a personalized cell therapy approach, while the in vivo program may support a more scalable route for reaching larger patient groups.
Company Sees Major Need in Inflammatory and Fibrotic Diseases
Resolution Therapeutics said inflammatory and fibrotic diseases remain areas of significant unmet medical need. These conditions can involve long-term tissue damage, persistent inflammation, scarring, and loss of organ function.
The company’s scientific approach focuses on the disease microenvironment. Instead of targeting only a single pathway, Regenerative Macrophage Therapy is designed to restore macrophage function and help restart the body’s natural repair processes.
Macrophages play important roles in inflammation, fibrosis, tissue repair, and immune regulation. Resolution believes that engineering macrophages with pro-regenerative properties may help address both inflammation and fibrosis, creating potential across a broad range of chronic diseases.
Regenerative Macrophage Therapy Targets Repair at the Microenvironment Level
Resolution’s Regenerative Macrophage Therapy platform is based on the idea that macrophages can influence the damaged tissue environment in multiple ways. These immune cells can help regulate inflammation, interact with scar-forming processes, and support repair signals.
The company is developing RMT to provide anti-inflammatory and anti-fibrotic effects. This dual activity is central to Resolution’s therapeutic strategy, especially in diseases where inflammation and fibrosis reinforce each other over time.
By focusing on restoring the function of macrophages, Resolution aims to support tissue regeneration rather than only slowing disease progression. The company believes this multimodal mechanism may offer broad potential in liver disease, graft-vs-host disease, lung fibrosis, and other inflammatory or fibrotic conditions.
Fast-Fail Strategy Intended to Accelerate Development
Resolution said its in vivo program has been designed around a fast-fail philosophy. This means the company plans to answer key technical questions early, using parallel testing to quickly determine which LNP formulations show the strongest potential.
Rather than relying on a single delivery system, the company will evaluate multiple differentiated LNP technologies. This approach is intended to increase the chance of identifying an optimal delivery vehicle while helping avoid delays caused by unsuitable candidates.
Resolution will also continue finalizing development of its proprietary payloads. The company said payload optimization will be important for improving the efficacy of in vivo RMT and supporting the selection of candidates for future studies.
CEO Says Program Marks a Decisive Inflection Point
Amir Hefni, Chief Executive Officer of Resolution Therapeutics, said the new program represents an important step in the company’s growth strategy.
“This programme marks a decisive inflection point for Resolution Therapeutics — an acceleration of ambition to match the urgent patient need,” said Hefni. “EMERALD, our autologous programme, is in the clinic with interim data expected later this year. We are building an in vivo platform to bring Regenerative Macrophage Therapy to more patients.”
The company said the in vivo program strengthens its long-term platform vision. If successful, the program could help Resolution move beyond individualized cell therapy approaches and develop broader delivery strategies for patients with inflammatory and fibrotic diseases.
Scientific Leadership Highlights Delivery and Payload Goals
Lara Campana, Scientific Co-Founder and Senior Vice President, Head of Research and Translational Science at Resolution Therapeutics, said the company’s deep knowledge of RMT biology gives it a strong foundation for building an in vivo platform.
“Resolution’s deep expertise in RMT biology, and how it mechanistically correlates with its clinical potential, offers a unique vantage point in building an in vivo RMT platform,” said Campana. “Our fail-fast approach is precisely what this scientific programme needs today.”
Campana added that a successful encapsulation and expression readout would directly support candidate nomination studies. She said such a result would also demonstrate that mRNA payloads can be delivered through an established and scalable modality.
In Vivo Delivery Could Become a Platform-Level Milestone
Resolution Therapeutics views successful LNP delivery validation as a potential platform-level milestone. The company said the ability to pair an effective LNP delivery system with a proprietary payload would extend the reach of Regenerative Macrophage Therapy and support future development across several disease areas.
While LNP delivery has been broadly validated in the biotechnology field, Resolution noted that each therapeutic application still requires careful optimization. Delivery must be suited to the payload, target cell type, route of administration, and intended biological effect.
For Resolution, the technical frontier is targeted delivery to the myeloid compartment outside of oncology. The company believes its focus on inflammatory and fibrotic disease provides a differentiated position in the field.
Resolution Aims to Build a Broader RMT Pipeline
The company’s initial focus remains RTX001 for end-stage liver disease, but Resolution is also advancing efforts to expand its platform into additional inflammatory and fibrotic indications.
These include graft-vs-host disease and lung fibrosis, areas where inflammation, immune dysfunction, and fibrosis can contribute to serious disease burden. Resolution believes its macrophage-based approach may offer potential across these settings because of its ability to influence the disease environment in several ways.
By developing both autologous and in vivo approaches, the company aims to create a flexible RMT pipeline. This strategy may allow Resolution to serve patients with severe disease through its clinical-stage autologous program while also exploring scalable in vivo solutions for broader patient access.
About Regenerative Macrophage Therapy
Regenerative Macrophage Therapy is a therapeutic approach designed to resolve inflammation and fibrosis at the microenvironment level. The strategy focuses on restoring macrophage function so these cells can support the body’s natural repair and regeneration processes.
Macrophages can have both anti-inflammatory and anti-fibrotic effects. By addressing these two drivers of chronic tissue damage, Regenerative Macrophage Therapy is designed to go beyond single-pathway treatment approaches.
Resolution Therapeutics is developing RMT as a multimodal platform with potential across inflammatory and fibrotic diseases. The company’s work includes autologous engineered macrophage therapy and an expanding in vivo program using LNP delivery technologies.
About Resolution Therapeutics
Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering Regenerative Macrophage Therapy in inflammatory and fibrotic diseases. The company uses its proprietary platform to develop macrophages with pro-regenerative properties, with the goal of improving outcomes for patients with serious diseases.
Resolution’s lead product candidate, RTX001, is being developed for patients with end-stage liver disease and has first-in-class potential supported by preclinical data showing anti-fibrotic and anti-inflammatory advantages compared with non-engineered macrophages.
The company is also working to expand the potential of its platform beyond liver disease, including inflammatory and fibrotic conditions such as graft-vs-host disease and lung fibrosis. Resolution is a spinout from Professor Stuart Forbes’s laboratory at the University of Edinburgh and is based in Edinburgh and London.
More information is available at https://resolution-tx.com/.
Company Contact
Louise Rowe
Vice President, Operations
Resolution Therapeutics
[email protected]
Media Contact
Optimum Strategic Communications
Stephen Adams, Joshua Evans, Aoife Minihan
[email protected]
+44 (0) 20 3821 6420
